Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

said Mr. David Allan, Chairman and CEO of YM BioSciences. "We look forward to the American Society of Hematology (ASH) meeting being held in early December 2010, where we expect that detailed initial clinical data from the Phase I and early Phase II portion of the study will be presented. More advanced data from the Phase II portion of the study are anticipated in mid-2011. We remain on track to advance CYT387 towards an NDA-enabling study, potentially in the latter half of 2011, and we are also reviewing opportunities for the compound in the numerous other indications in which evidence of activity has been shown with this family of molecules." Highlights from the first quarter:CYT387:

  • Mayo Clinic concluded dose-escalation in the Phase I portion of the Phase I/II clinical trial of CYT387 in patients with myelofibrosis, a chronic debilitating condition where the patient's bone marrow is replaced by scar tissue. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. The Chair of the trial announced that CYT387 showed significant activity in reducing spleen size and controlling constitutional symptoms in these patients. To date, 41 patients have been enrolled into the Phase II tranche bringing the total number in the study to 62. Given the favorable biological activity and safety data, the Company intends to expand enrolment for the trial up to 120 patients and include centers in the US, Canada and Australia, subject to regulatory approval.

  • CYT387 was granted Orphan Drug Designation by the US FDA in September.

  • Preclinical results for CYT387 were presented demonstrating that it possesses an excellent enzymatic potency and selectivity profile which may provide significant clinical advantages. The results were presented at the European School of Haematology International (ESH) International Conference on Myeloproliferative Neoplasms.

  • '/>"/>
    SOURCE YM BioSciences Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
    2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
    3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
    4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
    6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
    8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500â„¢
    9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
    10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
    11. Cell Biosciences to Acquire Convergent Bioscience
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
    (Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
    (Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
    (Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
    Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
    ... . - Radio frequency identification technology is often touted as ... health care world, the technology is bringing other, perhaps more ... on the supply chain now, and there are tremendous applications ... natural in the marketplace," said Reik Read, an analyst with ...
    ... IT businesses, according to market research firm Gartner, Inc. ... their key roles transformed. Ten percent will have closed their ... commodity status. , ,The predictions were made this week at ... changes are being driven by maturing IT applications and the ...
    ... Chippewa Valley Technical College in Eau Claire are offering ... surface analysis to firms or organizations with an economic ... three students will comprise each of five teams with ... that firms considering the purchase of an electron microscope ...
    Cached Biology Technology:RFID can be a matter of life and death in the medical world 2RFID can be a matter of life and death in the medical world 3RFID can be a matter of life and death in the medical world 4RFID can be a matter of life and death in the medical world 5Radical changes predicted for IT groups 2
    (Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
    (Date:10/18/2014)... patients with undiagnosed, suspected genetic conditions, a certain type ... molecular diagnostic yield than traditional molecular diagnostic methods, according ... study is being released to coincide with the American ... which sequences the protein­coding region of the genome (the ... a cell or organism), has been rapidly applied in ...
    (Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
    Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
    ... Bacteria in the human gut may not just be helping ... control over the metabolic functions of other organs, like the ... journal mBio . These findings offer new understanding of ... how changes to the microbiota can impact overall health. ...
    ... the silk moth,s antenna, University of Michigan researchers led ... that could advance understanding of a class of neurodegenerative ... work is newly published online in Nature Nanotechnology ... associate professor in the U-M departments of Biomedical Engineering ...
    ... Science fiction novelist and scholar Issac Asimov once said, ... that heralds new discoveries, is not ,Eureka!, but ,That,s funny., ... of researchers when they observed something they did not expect. ... of the Week," the Berlin-based team reports that it has ...
    Cached Biology News:Gut bacteria can control organ functions 2Silk moth's antenna inspires new nanotech tool with applications in Alzheimer's research 2Researchers develop curious snapshot of powerful retinal pigment and its partners 2Researchers develop curious snapshot of powerful retinal pigment and its partners 3